Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014;123:1647–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thompson PA, Siddiqi T. Treatment of Richter’s syndrome. Hematology. 2022;2022:329–36.

Article  PubMed  PubMed Central  Google Scholar 

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. NEJM. 2015;373:2425–37.

Article  CAS  PubMed  Google Scholar 

Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. NEJM. 2014;371:213–23.

Article  PubMed  Google Scholar 

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. NEJM. 2018;378:1107–20.

Article  CAS  PubMed  Google Scholar 

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. NEJM. 2014;370:2286–94.

Article  PubMed  Google Scholar 

Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36:369–384.e13.

Article  PubMed  PubMed Central  Google Scholar 

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2018;9:342–53.

Article  PubMed  Google Scholar 

Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023;29:158–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding W. Richter transformation in the era of novel agents. Hematology. 2018;2018:256–63.

Article  PubMed  PubMed Central  Google Scholar 

Croizier C, Guièze R. [Richter syndrome: diagnostic and therapeutic management]. Bull Cancer. 2021;108:521–7.

Article  PubMed  Google Scholar 

Nadeu F, Royo R, Massoni-Badosa R, Playa-Albinyana H, Garcia-Torre B, Duran-Ferrer M, et al. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. Nat Med. 2022;28:1662–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131:2761–72.

Article  CAS  PubMed  Google Scholar 

Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter’s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JCO. 2012;30:2211–7.

Article  Google Scholar 

Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, et al. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021;5:3528–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim HT, Baker PO, Parry E, Davids M, Alyea EP, Ho VT, et al. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation. Haematologica. 2021;106:3219–22.

Article  PubMed  PubMed Central  Google Scholar 

Puckrin R, Owen C, Fontaine A, Peters A, Stewart D, Shafey M. Allogeneic hematopoietic cell transplantation for Richter transformation of chronic lymphocytic leukemia: an intention-to-transplant analysis. Bone Marrow Transpl. 2023;58:817–9.

Article  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.

Article  Google Scholar 

Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute gvhd international consortium. Biol Blood Marrow Transpl. 2016;22:4–10.

Article  Google Scholar 

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. BBMT. 2015;21:389–401.e1.

Google Scholar 

Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from Hl-A-matched sibling donors. Transplantation. 1974;18:295–304.

Article  CAS  PubMed  Google Scholar 

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. JCO. 2014;32:3059–68.

Article  Google Scholar 

Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tournilhac O, Dreger P Chronic Lymphocytic Leukaemia. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, éditeurs. The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022; http://www.ncbi.nlm.nih.gov/books/NBK584167/.

Bensaber H, Bachy E, Beauvais D, Dulery R, Gastinne T, Villemagne B, et al. Anti-CD19 CAR T-Cell therapy for patients with Richter syndrome: a lysa study from the descar-T registry. Blood. 2022;140:3803–4.

Article  Google Scholar 

Guieze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, et al. Blinatumomab for patients with Richter syndrome: final results of the phase 2 blinart trial from the filo group. Blood. 2022;140:6631–2.

Article  Google Scholar 

Kater AP, Ye JC, Sandoval-Sus J, Bellido M, Christensen JH, Mato AR, et al. Subcutaneous epcoritamab in patients with Richter’s syndrome: early results from phase 1b/2 trial (EPCORE CLL-1). Blood. 2022;140:850–1.

Article  Google Scholar 

Carlo-Stella C, Hutchings M, Offner F, Mulvihill E, Relf J, Byrne B, et al. Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter’s transformation. Hematol Oncol. 2023;41:63–5.

Article  Google Scholar